Interestingly, IVIS bioluminescent imaging revealed the TGF-β combined treatment group showed marked suppression of tumor growth in the lungs with residual or relapsing tumor burden being predominantly observed in the liver rather than pulmonary tissue (Supplementary Figure 8B). Here, TGFB1 is linked to neoplasm.